Equities analysts expect Nuvectra Corp (NASDAQ:NVTR) to report $13.72 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Nuvectra’s earnings. The lowest sales estimate is $13.30 million and the highest is $14.51 million. Nuvectra reported sales of $13.15 million during the same quarter last year, which would suggest a positive year over year growth rate of 4.3%. The company is expected to report its next earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Nuvectra will report full-year sales of $57.61 million for the current year, with estimates ranging from $57.00 million to $58.52 million. For the next fiscal year, analysts forecast that the business will report sales of $70.97 million, with estimates ranging from $68.26 million to $76.25 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Nuvectra.
Nuvectra (NASDAQ:NVTR) last announced its quarterly earnings results on Wednesday, May 1st. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.18). The company had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $12.76 million. Nuvectra had a negative return on equity of 62.18% and a negative net margin of 98.77%.
Shares of Nuvectra stock traded down $0.22 during trading hours on Friday, reaching $5.16. The company’s stock had a trading volume of 6,325 shares, compared to its average volume of 328,204. Nuvectra has a one year low of $5.18 and a one year high of $25.17. The company has a quick ratio of 6.07, a current ratio of 6.60 and a debt-to-equity ratio of 0.56. The company has a market cap of $93.81 million, a PE ratio of -1.62 and a beta of -0.19.
In other Nuvectra news, Director David D. Johnson bought 20,000 shares of Nuvectra stock in a transaction dated Monday, May 6th. The shares were purchased at an average cost of $6.12 per share, for a total transaction of $122,400.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 2.90% of the company’s stock.
A number of large investors have recently modified their holdings of NVTR. PNC Financial Services Group Inc. grew its stake in Nuvectra by 231.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,318 shares of the company’s stock worth $54,000 after acquiring an additional 2,318 shares in the last quarter. BNP Paribas Arbitrage SA bought a new position in Nuvectra in the 1st quarter worth about $40,000. Metropolitan Life Insurance Co. NY grew its stake in Nuvectra by 356.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,108 shares of the company’s stock worth $83,000 after acquiring an additional 3,989 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new position in Nuvectra in the 1st quarter worth about $64,000. Finally, JPMorgan Chase & Co. grew its stake in Nuvectra by 89.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,375 shares of the company’s stock worth $92,000 after acquiring an additional 3,954 shares in the last quarter. Institutional investors own 82.58% of the company’s stock.
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.